APPENDIX 1A   |  APPENDIX 1B   |  APPENDIX 2A   |  APPENDIX 2B   |  APPENDIX 3   | 

 APPENDIX 4   |  APPENDIX 5   |  APPENDIX 6   |  APPENDIX 7   |  APPENDIX 8 | 

APPENDIX 6

Survival Using the Corrected Group Prognosis Method

Figure Appendix 6. Survival Distribution Function Compared Among Study Groups

Appendix 6 Figure Legends

Figure Appendix 6. Survival Distribution Function Compared Among Study Groups Using the Corrected Group Prognosis Method

Panel A: Adjusted survival distribution among 4345 patients by study group: control (1365 patients), aminocaproic acid (873 patients), tranexamic acid (821 patients), aprotinin (1286 patients).  Survival was significantly different between aprotinin and control (P < .001), but not between aminocaproic acid and control (P = .810), or between tranexamic acid and control (P = .641).  Survival was adjusted using the correct-group-prognosis method (see Methods). Patients participating in the in-hospital, but not long-term program were censored at 6 weeks.

Panel B: Adjusted survival distribution among patients without in-hospital death (n = 125): control (1330 patients, aminocaproic acid (847 patients), tranexamic acid (804 patients), aprotinin (1229 patients).